Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Redpoint Bio Corp. (RPBC.OB) Receives Patent Covering Screening Technology that may Offset Diabetes

|Includes: Redpoint Bio Corp. (RPBC)

Located in Ewing, New Jersey, Redpoint Bio is in the development of creating healthier and more tasteful foods that can contribute to the overall health of the world’s population. Today, Redpoint Bio announced they have received a new patent covering screening technology.

The patent is entitled “High Throughput Screening Assay for the TRPm5 Ion Channel.” Issued under Patent No. 7,749,730 B2 by the U.S. Patent and Trademark Office, the patent will cover methods of using high-throughput screen to discover certain modulators of the TRPm5 ion channel. The TRPm5 ion channel was originally identified as an important component of taste signaling circuits responsible for sensing sweet, savory, and bitter compounds on the tongue.

TRPm5 is critical to one’s health because it may be involved in the secretion of important hormones like GLP1 and insulin that control sugar uptake and metabolism. Consequently, modulators of TRPm5 could potentially find application as a new therapy for adult-onset diabetes and obesity which is currently affecting over 24 million Americans.

Ray Salemme, Ph.D., who serves as the company’s CEO, was quoted as saying, “This patent is part of our expanding portfolio in the TRPm5 area and reflects our continuing interest in investigating TRPm5 modulators as novel therapeutics for diabetes.”

To learn more about Redpoint Bio, visit the company website at:

Please see disclaimer on QualityStocks website:

Disclosure: no positions